These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3601094)

  • 1. Diurnal responsiveness to apomorphine.
    Gancher ST; Nutt JG
    Neurology; 1987 Jul; 37(7):1250-3. PubMed ID: 3601094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in the dopaminergic response during the day in Parkinson disease.
    Monge A; Viselli F; Stocchi F; Barbato L; Bolner A; Modugno N; Paradiso M; Ruggieri S; Nordera G
    Clin Neuropharmacol; 2004; 27(3):116-8. PubMed ID: 15190233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine and diphasic dyskinesia.
    Durif F; Deffond D; Dordain G; Tournilhac M
    Clin Neuropharmacol; 1994 Feb; 17(1):99-102. PubMed ID: 8149366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.
    Vaamonde J; Flores JM; Weisser R; Ibañez R; Obeso JA
    Mov Disord; 2009 Apr; 24(5):762-5. PubMed ID: 19224589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Verhagen Metman L; Locatelli ER; Bravi D; Mouradian MM; Chase TN
    Neurology; 1997 Feb; 48(2):369-72. PubMed ID: 9040723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
    Grandas F; Gancher ST; Rodriguez M; Lera G; Nutt JG; Obeso JA
    Clin Neuropharmacol; 1992 Feb; 15(1):13-8. PubMed ID: 1576595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.
    Gancher ST; Woodward WR; Gliessman P; Boucher B; Nutt JG
    Ann Neurol; 1990 Jun; 27(6):660-5. PubMed ID: 2360803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The motor response to repeated apomorphine administration in Parkinson's disease.
    Hughes AJ; Bishop S; Stern GM; Lees AJ
    Clin Neuropharmacol; 1991 Jun; 14(3):209-13. PubMed ID: 2070362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
    Turjanski N; Fernandez W; Lees AJ
    J Neurol Neurosurg Psychiatry; 1993 Jul; 56(7):771-5. PubMed ID: 8331352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F; Deffond D; Eschalier A; Tournilhac M
    Rev Neurol (Paris); 1992; 148(10):610-4. PubMed ID: 1295055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.